Thromb Haemost 2006; 95(05): 756-757
DOI: 10.1160/TH06-03-0162
Editorial Focus
Schattauer GmbH

Age-dependency of thrombin generation

H. Coen Hemker
1   Synapse b.v., Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
,
Raed Al Dieri
1   Synapse b.v., Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 20. März 2006

Accepted 21. März 2006

Publikationsdatum:
01. Dezember 2017 (online)

 

Footnote: This is Prof. Hemker’s 75th publication in Thrombosis and Haemostasis. Congratulations from the Editorial Office!


 
  • References

  • 1 Haidl H, Cimentil C, Leschnik B. et al. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006; 95: 772-5.
  • 2 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
  • 3 Kyrle PA, Mannhalter C, Beguin S. et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
  • 4 Regnault V, Beguin S, Wahl D. et al. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003; 89: 208-12.
  • 5 Nicolaes GA, Thomassen MC, Tans G. et al. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC- resistant individuals. Blood Coagul Fibrinolysis 1997; 08: 28-38.
  • 6 Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
  • 7 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol HaemostThromb 2003; 33: 4-15.
  • 8 Hemker HC, Siepel T, Altman R. et al. Kinetic aspects of the interaction of blood-clotting enzymes. II. The relation between clotting time and plasma concentration in prothrombin-time estimations. Thromb Diath Haemorrh 1967; 17: 349-57.
  • 9 Heras M, Chesebro JH, Webster MW. et al. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-84.
  • 10 Sambola A, Osende J, Hathcock J. et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-7.
  • 11 A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980; 02: 989-94.
  • 12 Neri GGSerneri, Modesti PA, Gensini GF. et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell’Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995; 345: 1201-4.
  • 13 Neri GGSerneri, Rovelli F, Gensini GF. et al. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 01: 937-42.
  • 14 Reverter JC, Beguin S, Kessels H. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and „clinical restenosis”. J Clin Invest 1996; 98: 863-74.